Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...
Bristol-Myers Squibb’s Cobenfy Launch Spurs ‘Buy’ Rating Amid Favorable Market Dynamics
Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...
Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco
Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...
MarketWatch7d
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slipped 1.45% to $49.02 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to ...
Sell Rating on Bristol-Myers Squibb Amid Competitive Pressures and Pricing Concerns
In a report released yesterday, Carter Gould from Barclays maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with ...
The Motley Fool25d
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
Benzinga.com10d
What Analysts Are Saying About Bristol-Myers Squibb Stock
8 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...